European Commission (EC) approved the bevacizumab (Avastin) as a medication in treating recurrent ovarian cancer resistant to chemotherapy containing platinum. Avastin has to be combined with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy....
Read more